Emyria Limited (ASX:EMD)

Market Cap	31.46M -30.5%
Revenue (ttm)	4.05M +190.6%
Net Income	-6.11M
EPS	-0.01
Shares Out	806.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,396,366
Open	0.0400
Previous Close	0.0400
Day's Range	0.0390 - 0.0400
52-Week Range	0.0360 - 0.0780
Beta	0.02
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the Universi...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In fiscal year 2026, Emyria's revenue was 4.05 million, an increase of 190.62% compared to the previous year's 1.39 million. Losses were -6.11 million, 94.6% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 20, 2026

Data Sources Report a data error